Tarsus Pharmaceuticals, Inc. TARS Incentive From Lessor
Incentive From Lessor at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncentiveFromLessor.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
the Company became entitled to base rent abatement for the first five full calendar months for an aggregate amount of $0.7 million. The Current Lease also provides a tenant improvement allowance, not to exceed approximately $5.8 million, and to be applied toward construction costs of the premises. The tenant improvement allowance must be used within one year of the Current Lease commencement date, after which any unused portion will be forfeited with no further obligation by the landlord. As of June 30, 2026, the landlord paid $5.3 million of the tenant improvement allowance.
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s incentive from lessor?
- Tarsus Pharmaceuticals, Inc. (TARS) reported incentive from lessor of $700K in Q4 2024.
- What does incentive from lessor mean?
- This refers to financial concessions or benefits provided by a landlord to a tenant, such as rent holidays or cash contributions. These incentives are used to offset initial occupancy costs and are typically amortized over the life of the lease.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s incentive from lessor.
Connect your AI assistant and compare it to peers, right in your chat.
